Ivim Health Review 2026
Reviewed August 7, 2026 · Both — compounded tirzepatide and microdosing alongside brand-name Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, the Wegovy pill and Foundayo.
Visit Ivim Health WebsiteOverview
Ivim Health is a weight and hormone health platform that does something no other provider in this directory does: it publishes peer-reviewed outcomes from its own patient population in Obesity Pillars, a journal of the Obesity Medicine Association. That single fact reframes how to read everything else about it. Across these reviews we have repeatedly flagged unsourced efficacy claims — a '96.8% success rate' with nothing attached, 'Up to 22% avg' borrowed from brand-drug trials, 'lose 20% of your body weight' lifted from SURMOUNT-1 and applied to compounded product. Ivim instead subjected its results to external peer review, which is the actual answer to the question every marketing claim in this market gestures at. Its formulary is correspondingly serious: compounded tirzepatide at $133/month on a six-month plan and a microdosing programme, alongside a complete brand-name range covering Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, the Wegovy pill and Foundayo, so a clinician can prescribe FDA-approved product where it fits. It states around 100 board-certified providers, unlimited same-day provider visits across all programmes, and more than 470,000 patients served. It also lists non-GLP-1 metabolic options — berberine, B12, lipotropic, fibre — for patients who want or need something other than a GLP-1. The reservations are ordinary: membership is charged separately from medication, the $133 rate needs a six-month commitment, the compounded products carry the usual caveats, and a large supplement range sits alongside the prescriptions on thinner evidence.
Medications Offered
Brand-name or compounded: Both — compounded tirzepatide and microdosing alongside brand-name Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, the Wegovy pill and Foundayo.
- Compounded tirzepatide — $133/month on a six-month plan
- GLP-1 microdosing programme
- Wegovy® pill — the first FDA-approved oral GLP-1
- Foundayo™ pill (orforglipron)
- Brand-name Zepbound®, Mounjaro®, Ozempic®, Wegovy® and Saxenda®
- Liraglutide
- Metabolic support: berberine, B12, lipotropic, fibre, vitamin D3+K2, greens
- Hormone health programmes for women and men
Consultation Process
Choose your programme
Ivim organises by goal — weight loss, women's hormone health, men's hormone health — then by programme (GLP-1, compounded, microdosing) and by medication.
Provider visit
Ivim states it has around 100 board-certified providers and offers unlimited same-day provider visits across all programmes. Same-day access during titration is a genuine practical advantage.
Compounded or brand-name
Because the formulary spans both, ask whether an FDA-approved option suits you before accepting compounded product. The Wegovy pill and Foundayo give oral approved routes.
Ongoing care under membership
Membership covers clinical access and is charged separately from medication. The $133/month compounded tirzepatide rate requires a six-month plan.
Eligibility
- Adults; provider assessment determines suitability
- FDA-approved GLP-1 indications apply to the brand-name route: BMI 30+, or 27+ with a weight-related comorbidity
- Non-GLP-1 metabolic options available for patients who do not qualify or prefer them
- State availability is not published on the pages we reviewed
- Standard GLP-1 contraindications apply
Provider Involvement
Among the strongest here. Ivim states around 100 board-certified providers and unlimited same-day provider visits across all programmes — same-day access matters most precisely when it is hardest to get, during dose escalation and side-effect management. It also publishes a research section and named clinical voices; Dr Jessica Duncan is identified as having testified before the FDA on peptide access. A provider that publishes peer-reviewed outcomes and puts named clinicians into public regulatory debate is operating at a different level of clinical seriousness from the questionnaire-and-ship platforms elsewhere in this directory.
Lab Requirements
Not published on the pages we reviewed. Ask what baseline and ongoing monitoring applies to your programme.
Pharmacy Fulfillment
Brand-name products are manufacturer product. Compounded tirzepatide and the microdosing formulations come from an unnamed compounding pharmacy — the main disclosure gap in an otherwise strong picture. Ask which facility and its 503A/503B status.
Shipping Frequency
Not published. Confirm cadence and cold-chain handling for injectables.
Membership Fees vs. Medication Fees
Membership fees
Membership is charged separately from medication; a $75 figure appears on Ivim's pages consistent with a membership rate. Confirm your specific membership charge and what it includes before enrolling.
Medication fees
- Compounded tirzepatide: $133/month on a six-month plan
- Membership: charged separately, with $75 appearing on Ivim's pages
- Brand-name Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, Wegovy pill and Foundayo: priced by product and coverage
- Supplements and metabolic support priced separately
Cancellation & Refund Policy
Cancellation
Not published on the pages we reviewed. Because the $133 rate is tied to a six-month plan, establish the mid-term cancellation position in writing before committing.
Refunds
Not published on the pages we reviewed.
Insurance
Not detailed on the pages we reviewed, but because Ivim offers the full brand-name range, those prescriptions are in principle coverable on a pharmacy benefit. Ask whether Ivim can route a brand-name prescription through your own insurance rather than charging cash.
HSA / FSA
Not stated on the pages we reviewed. Confirm directly.
See our GLP-1 insurance and HSA/FSA guide for how reimbursement works in practice.
Support Services
- Unlimited same-day provider visits across all programmes
- Around 100 board-certified providers
- Published research and resource centre
- Corporate programme for employers
- Hormone health programmes alongside weight care
State Availability
Not published on the pages we reviewed.
Pros
- Publishes peer-reviewed patient outcomes in Obesity Pillars — the only provider in this directory to do so
- Compounded tirzepatide at $133/month on a six-month plan
- Full brand-name formulary: Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, plus the Wegovy pill and Foundayo
- Around 100 board-certified providers with unlimited same-day visits across all programmes
- States 470,000+ patients served
- Offers a microdosing programme alongside standard dosing
- Non-GLP-1 metabolic support available: berberine, B12, lipotropic, fibre
Cons
- Membership is a separate charge on top of medication
- The $133 tirzepatide rate requires a six-month commitment
- Compounded products remain in the catalogue and are not FDA-approved
- Large supplement range sold alongside prescriptions, some on thin evidence
- No named compounding pharmacy
- Cancellation and refund terms are not published on the pages we reviewed
Who Ivim Health May Be Best For
- Patients who want a provider that can show evidence for its own results
- Anyone who wants same-day clinical access during titration
- People who want a clinician choosing across compounded, brand-name, oral and microdosed options
- Patients who may need a non-GLP-1 route
Limitations
- Membership charged separately from medication
- Six-month commitment for the headline compounded rate
- Unnamed compounding pharmacy
- No published cancellation or refund terms or state list
- Large supplement range on thinner evidence than the prescription side
Reputation & Trust
IMPORTANT UPDATE, 7 August 2026: we revised this assessment down from 4.5/5 after verifying an FDA warning letter against the company. On 20 February 2026 the FDA issued Ivim Services LLC warning letter MARCS-CMS 721816, finding its compounded semaglutide and tirzepatide products misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The specific finding: the compounded products displayed on its website 'identify "Ivim" on the pictured label, suggesting Ivim is the compounder of those drugs when in fact it is not'. We confirmed this in the FDA's own warning letter database. Ivim was one of 30 telehealth companies warned in the sweep the FDA announced on 3 March 2026, and the letter concerns labelling and marketing rather than any finding about medication safety. It is a genuinely awkward finding for this provider specifically, because the rest of its profile is built on evidential seriousness — and putting your own name on a label for a product you did not compound is a disclosure failure, not a technicality. Everything below remains accurate and is worth weighing against it. Ivim is the most clinically credible operator we have reviewed in this round, and the reason is specific rather than impressionistic. It has published patient outcomes in Obesity Pillars, a peer-reviewed journal of the Obesity Medicine Association. Across this directory we have documented provider after provider making efficacy claims with nothing behind them — a 96.8% success rate with no definition, 'Up to 22% avg' taken from brand-drug registration trials and shown beside compounded product, 'lose 20% of your body weight' borrowed from SURMOUNT-1. Submitting your own results to external peer review is the opposite of that, and it is the single strongest trust signal available to a company in this market. Around it sit consistent supporting facts: roughly 100 board-certified providers, unlimited same-day provider visits, more than 470,000 patients served, a complete brand-name formulary alongside compounded options so clinicians are not constrained to unapproved product, non-GLP-1 metabolic alternatives, and named clinicians engaging publicly with the FDA on regulatory questions. The gaps are the ordinary commercial ones — separate membership charge, a six-month commitment behind the headline rate, an unnamed compounding pharmacy, no published cancellation or refund terms, and a large supplement range whose evidence base is thinner than the prescription side.
What Makes Ivim Health Different
- Peer-reviewed patient outcomes published in Obesity Pillars — unique in this directory
- Unlimited same-day provider visits across all programmes
- Complete brand-name formulary including the Wegovy pill and Foundayo
- Around 100 board-certified providers and 470,000+ patients served
- Microdosing and non-GLP-1 metabolic options as well as standard dosing
Our Verdict
Ivim Health earns 3.5/5, revised down from 4.5/5 on 7 August 2026 after we verified an FDA warning letter against it. On 20 February 2026 the FDA found Ivim's compounded semaglutide and tirzepatide misbranded because the products pictured on its website carried labels identifying 'Ivim' as the compounder 'when in fact it is not' — one of 30 telehealth firms warned in that sweep. That is a real disclosure failure and it lands awkwardly here, because everything else about this provider is built on evidential seriousness. The rest of our assessment stands and is worth weighing against it. Ivim is the only provider across this entire directory that has published patient outcomes in a peer-reviewed journal — Obesity Pillars, from the Obesity Medicine Association. Set that against what we have documented elsewhere in this same review round: a '96.8% success rate' with no definition or source, brand-drug registration-trial percentages displayed beside compounded product, and 'lose 20% of your body weight' lifted from SURMOUNT-1 by a company selling something SURMOUNT-1 never studied. Submitting your own results to external peer review is not a marketing tactic; it is the thing all those claims are pretending to be. The rest of the offering supports it: around 100 board-certified providers, unlimited same-day visits when you actually need them, a complete brand-name formulary including the Wegovy pill and Foundayo alongside compounded tirzepatide at $133/month, microdosing, non-GLP-1 metabolic options, and named clinicians engaging publicly with the FDA. The reservations are ordinary — membership billed separately, a six-month commitment behind the headline rate, an unnamed compounding pharmacy, unpublished cancellation terms, and a supplement range thinner than the prescription side. Ask for your all-in figure and the cancellation terms, then this is among the best options here.
Alternatives to Ivim Health
The closest comparison on disclosure quality, with the clearest published efficacy footnote in this directory.
FDA-approved medication only, with board-certified physicians and no minimum commitment.
Also publishes its own clinical research, with lab testing to 146 markers.
Brand-name only with an insurance coordinator, at a published $74/month membership.
Compare more options on our best online GLP-1 providers and cheapest GLP-1 programs pages.
Frequently Asked Questions
What makes Ivim different from other GLP-1 providers?
It publishes peer-reviewed outcomes from its own patients in Obesity Pillars, a journal of the Obesity Medicine Association. No other provider in this directory does that. Most make efficacy claims with nothing behind them — we found a '96.8% success rate' with no definition and brand-drug trial percentages shown next to compounded product. Submitting your own results for external peer review is a genuinely different standard of evidence.
What does Ivim cost?
Compounded tirzepatide is published at $133/month on a six-month plan, with membership charged separately — a $75 figure appears on its pages consistent with a membership rate. Brand-name products including Wegovy, Zepbound, Mounjaro, Ozempic and the Wegovy pill are priced by product and coverage. Ask for your all-in monthly figure covering both membership and medication.
Does Ivim offer FDA-approved medication?
Yes, and its formulary is one of the most complete here: Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, plus the Wegovy pill — the first FDA-approved oral GLP-1 — and Foundayo. That means a clinician can prescribe approved product where it fits rather than defaulting to compounded material. Ask specifically whether an approved option suits you.
What if I cannot take a GLP-1?
Ivim lists non-GLP-1 metabolic support including berberine, B12, lipotropic injections and fibre, alongside hormone health programmes for women and men. That gives options if a GLP-1 is unsuitable, though note these supplements have a considerably thinner evidence base than the prescription medications — discuss what is actually worth taking with the provider.
How quickly can I speak to a provider?
Ivim states it offers unlimited same-day provider visits across all programmes, with around 100 board-certified providers. Same-day access matters most during dose escalation and when managing side effects, which is exactly when most competitors make you wait or charge extra.
Important Notes & Warnings
- This review is informational only and is not medical advice. Consult a licensed clinician before starting or changing treatment.
- REGULATORY: Ivim Services LLC received FDA warning letter MARCS-CMS 721816 on 20 February 2026, finding its compounded semaglutide and tirzepatide products misbranded under FD&C Act sections 502(a) and 502(bb). The FDA found the product labels shown on its website identified 'Ivim' as the compounder 'when in fact it is not'.
- Ask which pharmacy actually compounds your medication and confirm its 503A or 503B status before ordering.
- Compounded tirzepatide and microdosed formulations are NOT FDA-approved and are not therapeutically equivalent to brand-name products beyond the shared active ingredient.
- Membership is charged separately from medication — budget for both.
- The $133/month compounded tirzepatide rate requires a six-month plan, and no cancellation or refund terms are published.
- Microdosing is not an FDA-approved dosing strategy and lacks the outcome evidence behind standard dosing.
- Supplements sold alongside prescriptions have a thinner evidence base — they are not required for GLP-1 treatment.
- No compounding pharmacy is named — ask which facility fills your prescription and its 503A status.
- GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and in pregnancy.
- Common side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain; serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration.
Sources
- Ivim Health programme, medication and research pages, ivimhealth.com (accessed 7 August 2026)
- Ivim Health peer-reviewed patient outcomes published in Obesity Pillars
- FDA-approved indications for Wegovy, Zepbound, Mounjaro, Ozempic and Saxenda
Medical Disclaimer
This review is for informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with real risks and contraindications. Only a licensed clinician who has evaluated you can decide whether any medication is appropriate. Talk to a healthcare provider before starting, changing, or stopping any treatment, and call emergency services for urgent symptoms.
Facts in this review were compiled from the provider's own public website and public search results as of August 7, 2026. Prices, medication availability, pharmacy partners, and policies change frequently and vary by state — verify everything directly with the provider before purchasing.
This page contains affiliate links. We may earn a commission from qualifying purchases at no additional cost to you.